Ginkgo Bioworks
DNA | NYSE
$8.50
-$1.11 (-11.55%)
At close: Nov 16, 2026, 4:00 PM ET
$8.54
+$0.04 (+0.47%)
After-hours:
Nov 16, 2026, 7:41 PM ET
-11.55%
(1D)Rating
37
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #613/1021 (Top 60%)
Key Statistics
Market Data
Market Cap $551.01M
1D Range
8.35 9.30
52W Range
5.48 14.98
Valuation (TTM)
PE -2.02
PB 1.40
EV/EBITDA -3.03
Valuation (NTM)
Forward PE N/A
Forward PEG 0.10
Price Target $5.00
Cash Flow
FCF Yield -33.9%
SBC Adj. FCF Yield -43.3%
SBC Impact -28.0%
Margins
Gross Margin 88.8%
Operating Margin -334.6%
FCF Margin -255.4%
Growth (CAGR)
Revenue 3Y | 5Y -38.6% |
-18.0%
Dil EPS 3Y | 5Y 55.8% |
70.0%
FCF 3Y | 5Y 39.6% |
17.7%
Returns
ROA -26.6%
ROE -56.9%
ROIC -27.7%
Financial Health
Net Debt
$111.84M
Current Ratio 4.72
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The co...
Sector Healthcare
Industry Biotechnology
Employees 485
IPO Date Apr 19, 2021
Website www.ginkgo.bio
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.64
Beat +5.59%
YoY:
+55.86% REV
$27.71M
Beat +28.89%
YoY:
-28.65%Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$5.00
Downside
-41.18%
Buy (0)
Hold (1)
Sell (1)
Add to Watchlist
Select watchlists to add or remove DNA